RESUMO
Although current data shows that chromium supplementation in type 2 Diabetic patients can improve control blood sugar and lipids there are controversial results about its relevance to improving blood sugar and lipids in diabetes. This study investigates the effect of chromium picolinate supplement on blood sugar and lipids control in patients with type 2 diabetes. This randomized, double-blind,placebo-controlled study was carried out at the Diabetes Clinic of the Loghman Hospital in collaboration with Taban Diabetes Clinic. In this clinical study of 60 patients with type 2 Diabetes, participants were randomized into the doubleblind treatment and control groups for 3 months of treatment with 200 g of chromium picolinate or placebo respectively. Blood sugar and lipids profile were assessed at the beginning and end of the study. Based on the result of this study it has been found that 200 micrograms of chromium consumed over three months could decrease of TG levels dramatically, compared to placebos. TG changes were significantly different between the two groups, [P=0.048], without any change in other lipid profiles of the two groups. Findings showed that chromium picolinate treatment for 90 days produced significant improvements in glycemic control compared to placebo, based on significant reductions in both FPG and HbA1c levels in patients with type 2 diabetes mellitus, with significant changes between the two groups [P<0.001]. Results of this study recommend that chromium picolinate prescribed to type 2 diabetes patients could decrease TG, HbA1c and FPG levels
RESUMO
To determine the correlation between presumed risk factors and diabetic retinopathy [DR] in patients with type II diabetes mellitus [DM]. This descriptive analytical study was performed on medical records of patients with type II DM referred to a diabetes clinic in Birjand Valiasr Hospital from September 2006 to September 2007. Parameters included age, sex, duration of DM, type of ocular involvement, blood lipid profile and levels of fasting blood sugar [FBS] and hemoglobin A1C [Hb A1C]. The study included 359 patients with mean age of 51.2 +/- 0.8 [range 35-65] years including 66.6% female subjects. Duration of DM was less than 5 years in 54.2%. Overall, 37.3% of patients had ocular involvement including non-proliferative retinopathy in 71.6%, proliferative retinopathy in 20.2% and cataracts in 3.0%. There was a positive correlation between presence of retinopathy and DM duration [P=0.001], age [P=0.006], male sex [P=0.002], high FBS levels [P=0.03] and low Hb A1C levels [P=0.001] but there was no significant correlation between retinopathy and blood lipid profile. Duration of diabetes, aging, male sex, high FBS levels and low Hb A1C levels increase the chance for developing diabetic retinopathy in patients with diabetes mellitus type 2